Charity Breast Cancer Now has described the failure to negotiate a fair price of Enhertu as “utterly heartbreaking”.

AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...

Although AstraZeneca, Daiichi Sankyo and England’s drug cost watchdog have spent months trying to hash out a fair price for ...

Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers ...

Breast cancer drug blocked for NHS use as price talks break down for third time - Nice said it was ‘extremely disappointed’ ...

LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...

Discussions aimed at making AstraZeneca and Daiichi Sankyo's Enhertu available to breast cancer patients on the NHS have been ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

Low event rates and short TTRs with warfarin were notable, and questions persist as to which patients truly need OAC.